{
"id": "https://doi.org/10.6084/m9.figshare.14446833.v1",
"doi": "10.6084/M9.FIGSHARE.14446833.V1",
"url": "https://tandf.figshare.com/articles/journal_contribution/The_synergistic_antitumor_activity_of_3-_2-nitrophenyl_propionic_acid-paclitaxel_nanoparticles_NPPA-PTX_NPs_and_anti-PD-L1_antibody_inducing_immunogenic_cell_death/14446833/1",
"types": {
"ris": "RPRT",
"bibtex": "article",
"citeproc": "article-journal",
"schemaOrg": "ScholarlyArticle",
"resourceType": "Journal contribution",
"resourceTypeGeneral": "Text"
},
"creators": [
{
"name": "Duan, Xiao-Chuan",
"givenName": "Xiao-Chuan",
"familyName": "Duan"
},
{
"name": "Peng, Li-Yuan",
"givenName": "Li-Yuan",
"familyName": "Peng"
},
{
"name": "Yao, Xin",
"givenName": "Xin",
"familyName": "Yao"
},
{
"name": "Xu, Mei-Qi",
"givenName": "Mei-Qi",
"familyName": "Xu"
},
{
"name": "Li, Hui",
"givenName": "Hui",
"familyName": "Li"
},
{
"name": "Zhang, Shuai-Qiang",
"givenName": "Shuai-Qiang",
"familyName": "Zhang"
},
{
"name": "Li, Zhuo-Yue",
"givenName": "Zhuo-Yue",
"familyName": "Li"
},
{
"name": "Wang, Jing-Ru",
"givenName": "Jing-Ru",
"familyName": "Wang"
},
{
"name": "Feng, Zhen-Han",
"givenName": "Zhen-Han",
"familyName": "Feng"
},
{
"name": "Wang, Guang-Xue",
"givenName": "Guang-Xue",
"familyName": "Wang"
},
{
"name": "Liao, Ai",
"givenName": "Ai",
"familyName": "Liao"
},
{
"name": "Chen, Ying",
"givenName": "Ying",
"familyName": "Chen"
},
{
"name": "Zhang, Xuan",
"givenName": "Xuan",
"familyName": "Zhang"
}
],
"titles": [
{
"title": "The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death"
}
],
"publisher": {
"name": "Taylor & Francis"
},
"container": {},
"subjects": [
{
"subject": "Biophysics"
},
{
"subject": "Space Science"
},
{
"subject": "Medicine"
},
{
"subject": "Cell Biology"
},
{
"subject": "Physiology"
},
{
"subject": "FOS: Biological sciences",
"schemeUri": "http://www.oecd.org/science/inno/38235147.pdf",
"subjectScheme": "Fields of Science and Technology (FOS)"
},
{
"subject": "Pharmacology"
},
{
"subject": "Immunology"
},
{
"subject": "FOS: Clinical medicine",
"schemeUri": "http://www.oecd.org/science/inno/38235147.pdf",
"subjectScheme": "Fields of Science and Technology (FOS)"
},
{
"subject": "Biological Sciences not elsewhere classified"
},
{
"subject": "Cancer"
},
{
"subject": "Hematology"
}
],
"contributors": [],
"dates": [
{
"date": "2021-04-19",
"dateType": "Created"
},
{
"date": "2024-03-21",
"dateType": "Updated"
},
{
"date": "2021",
"dateType": "Issued"
}
],
"publicationYear": 2021,
"identifiers": [],
"sizes": [
"847603 Bytes"
],
"formats": [],
"rightsList": [
{
"rights": "Creative Commons Attribution 4.0 International",
"rightsUri": "https://creativecommons.org/licenses/by/4.0/legalcode",
"schemeUri": "https://spdx.org/licenses/",
"rightsIdentifier": "cc-by-4.0",
"rightsIdentifierScheme": "SPDX"
}
],
"descriptions": [
{
"description": "Cancer immunotherapy is a strategy that is moving to the frontier of cancer treatment in the current decade. In this study, we show evidence that 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs), act as immunogenic cell death (ICD) inducers, stimulating an antitumor response which results in synergistic antitumor activity by combining anti-PD-L1 antibody (aPD-L1) in vivo. To investigate the antitumor immunity induced by NPPA-PTX NPs, the expression of both ICD marker calreticulin (CRT) and high mobility group box 1 (HMGB1) were analyzed. In addition, the antitumor activity of NPPA-PTX NPs combined with aPD-L1 in vivo was also investigated. The immune response was also measured through quantitation of the infiltration of T cells and the secretion of pro-inflammatory cytokines. The results demonstrate that NPPA-PTX NPs induce ICD of MDA-MB-231 and 4T1 cells through upregulation of CRT and HMGB1, reactivating the antitumor immunity via recruitment of infiltrating CD3+, CD4+, CD8+ T cells, secreting IFN-γ, TNF-α, and the enhanced antitumor activity by combining with aPD-L1. These data suggest that the combined therapy has a synergistic antitumor activity and has the potential to be developed into a novel therapeutic regimen for cancer patients.",
"descriptionType": "Abstract"
}
],
"geoLocations": [],
"fundingReferences": [],
"relatedIdentifiers": [
{
"relationType": "IsIdenticalTo",
"relatedIdentifier": "10.6084/m9.figshare.14446833",
"relatedIdentifierType": "DOI"
},
{
"relationType": "IsSupplementTo",
"relatedIdentifier": "10.1080/10717544.2021.1909180",
"relatedIdentifierType": "DOI"
}
],
"relatedItems": [],
"schemaVersion": "http://datacite.org/schema/kernel-4",
"providerId": "otjm",
"clientId": "figshare.ars",
"agency": "datacite",
"state": "findable"
}